Anca Askanase, MD, MPH

Director
Columbia University Medical Center
New York, NY, United States

Academic rheumatologist

Amgen (Individual(s) Involved: Self; Ongoing): Advisor or Review Panel member; AstraZeneca (Individual(s) Involved: Self; Ongoing): Advisor or Review Panel member, Grant/Research Support; Aurinia (Individual(s) Involved: Self; Ongoing): Advisor or Review Panel member; Eli Lilly (Individual(s) Involved: Self; Ongoing): Grant/Research Support; GlaxoSmithKlein(GSK) (Individual(s) Involved: Self; Ongoing): Advisor or Review Panel member; Idorsia (Individual(s) Involved: Self; Ongoing): Grant/Research Support; Janssen (Individual(s) Involved: Self; Ongoing): Grant/Research Support; Pfizer (Individual(s) Involved: Self; Ongoing): Grant/Research Support; UCB (Individual(s) Involved: Self; Ongoing): Grant/Research Support

Presentation(s):

• 204: Changing the Course of Disease in Lupus

  Monday, October 31, 2022
  10:00 AM – 10:05 AM Eastern Time

• 212: SLE Pathophysiology in 2022

  Monday, October 31, 2022
  10:00 AM – 10:05 AM Eastern Time

• 12S135: State-of-the-Art: Lupus State of the Art: Biomarkers Genetics and Phenotyping

  Saturday, November 12, 2022
  3:30 PM – 4:30 PM Eastern Time

• 223: Biologics in Lupus – Why, Who, and When?

  Saturday, November 12, 2022
  6:30 PM – 8:30 PM Eastern Time

• 1442: Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus

  Sunday, November 13, 2022
  1:00 PM – 3:00 PM Eastern Time

• 1656: Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2b Trial

  Monday, November 14, 2022
  10:15 AM – 10:25 AM Eastern Time

• 609: CH Systemic Lupus Erythematosus: Novel Therapies for SLE

  Monday, November 14, 2022
  1:00 PM – 2:00 PM Eastern Time